Kei Nakata

780 total citations
33 papers, 564 citations indexed

About

Kei Nakata is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Kei Nakata has authored 33 papers receiving a total of 564 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Epidemiology. Recurrent topics in Kei Nakata's work include Cardiac Imaging and Diagnostics (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Cardiovascular Function and Risk Factors (5 papers). Kei Nakata is often cited by papers focused on Cardiac Imaging and Diagnostics (7 papers), Liver Disease Diagnosis and Treatment (5 papers) and Cardiovascular Function and Risk Factors (5 papers). Kei Nakata collaborates with scholars based in Japan and United States. Kei Nakata's co-authors include Masaya Tanno, Toshiyuki Yano, Tetsuji Miura, Takayuki Miki, Tatsuya Sato, Atsushi Kuno, Yukishige Kimura, H Oshima, Masashi Mizuno and Koki Abe and has published in prestigious journals such as Circulation, PLoS ONE and Scientific Reports.

In The Last Decade

Kei Nakata

27 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kei Nakata Japan	11	253	234	159	111	101	33	564
Gaetana Albanese Italy	9	302 1.2×	241 1.0×	156 1.0×	189 1.7×	70 0.7×	11	624
Vadim V. Klimontov Russia	15	388 1.5×	170 0.7×	220 1.4×	81 0.7×	122 1.2×	101	799
Poorna R. Karuparthi United States	12	205 0.8×	122 0.5×	182 1.1×	217 2.0×	55 0.5×	30	647
Leann Olansky United States	16	408 1.6×	305 1.3×	185 1.2×	81 0.7×	81 0.8×	29	726
Maxime Pellegrin Switzerland	12	86 0.3×	255 1.1×	113 0.7×	195 1.8×	122 1.2×	33	651
Salva R. Yurista United States	11	401 1.6×	281 1.2×	175 1.1×	337 3.0×	37 0.4×	25	793
H. J. Arnqvist Sweden	13	370 1.5×	284 1.2×	269 1.7×	76 0.7×	47 0.5×	27	770
Ji Hu China	13	157 0.6×	110 0.5×	90 0.6×	53 0.5×	48 0.5×	33	460
Daphne Yau United Kingdom	12	245 1.0×	249 1.1×	170 1.1×	37 0.3×	83 0.8×	27	541
Yoshikazu Nitta Japan	10	174 0.7×	116 0.5×	77 0.5×	181 1.6×	113 1.1×	16	629

Countries citing papers authored by Kei Nakata

Since Specialization

Citations

This map shows the geographic impact of Kei Nakata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Nakata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Nakata more than expected).

Fields of papers citing papers by Kei Nakata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Nakata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Nakata. The network helps show where Kei Nakata may publish in the future.

Co-authorship network of co-authors of Kei Nakata

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Nakata. A scholar is included among the top collaborators of Kei Nakata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Nakata. Kei Nakata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Marenao, Tatsuya Sato, Kei Nakata, et al.. (2025). High Level of Estimated Small Dense Low-Density Lipoprotein Cholesterol as an Independent Risk Factor for the Development of Ischemic Heart Disease Regardless of Low-Density Lipoprotein Cholesterol Level　― A 10-Year Cohort Study ―. Circulation Journal. 89(8). 1182–1189. 2 indexed citations

Nishikawa, Ryo, Toshiyuki Yano, Kei Nakata, et al.. (2025). Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy. Circulation Heart Failure. 18(5). e012234–e012234.

Tanaka, Marenao, Tatsuya Sato, Tomohito Gohda, et al.. (2025). Elevated urinary fatty acid-binding protein 4 level predicts future renal dysfunction and poor prognosis in Japanese patients with diabetes: a longitudinal cohort study. Clinical Kidney Journal. 18(4). sfaf056–sfaf056.

Suzuki, Toru, et al.. (2025). Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 16. 1496671–1496671.

Koyama, Masayuki, et al.. (2025). Effects of physical activity-promoting wearable devices on blood pressure in adults: a systematic review and meta-analysis. Hypertension Research. 48(10). 2677–2687.

Tanaka, Marenao, Tatsuya Sato, Yukinori Akiyama, et al.. (2025). Incorporation of Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Health Stage of Cardiovascular‐Kidney‐Metabolic Syndrome Improves Predictive Ability for Coronary Artery Disease in a Japanese General Population. Journal of the American Heart Association. 14(16). e043173–e043173. 1 indexed citations

Suzuki, Toru, Tatsuya Sato, Marenao Tanaka, et al.. (2024). Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications. 38(7). 108779–108779. 6 indexed citations

Mori, Kazuma, Marenao Tanaka, Tatsuya Sato, et al.. (2024). Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period. Hepatology Research. 55(1). 34–45. 14 indexed citations

Nakata, Kei, et al.. (2024). Science behind children’s handwashing: action study of 9- to 10-years-old elementary school students in Japan. Frontiers in Public Health. 12. 1425646–1425646.

10.

Tanaka, Marenao, Tatsuya Sato, Tomohito Gohda, et al.. (2024). Urinary fatty acid‐binding protein 4 is a promising biomarker for glomerular damage in patients with diabetes mellitus. Journal of Diabetes Investigation. 16(4). 670–679. 1 indexed citations

11.

Nakamura, Satoshi, Masaki Ishida, Kei Nakata, et al.. (2023). Complementary prognostic value of stress perfusion imaging and global coronary flow reserve derived from cardiovascular magnetic resonance: a long-term cohort study. Journal of Cardiovascular Magnetic Resonance. 25(1). 20–20. 5 indexed citations

12.

Kobayashi, Ryo, Makito Tanaka, Marenao Tanaka, et al.. (2023). Validation of Estimated Small Dense Low-Density Lipoprotein Cholesterol Concentration in a Japanese General Population. Journal of Atherosclerosis and Thrombosis. 31(6). 931–952. 8 indexed citations

13.

Takafuji, Masafumi, Masaki Ishida, Satoshi Nakamura, et al.. (2023). Microvascular Dysfunction in Patients with Idiopathic Dilated Cardiomyopathy: Quantitative Assessment with Phase Contrast Cine MR Imaging of the Coronary Sinus. Magnetic Resonance in Medical Sciences. 24(1). 10–19. 4 indexed citations

14.

Murakami, Hiroaki, Naoki Fujimoto, Kei Nakata, et al.. (2020). Serial cardiac magnetic resonance imaging in wet beriberi. Journal of Cardiology Cases. 22(3). 100–102. 1 indexed citations

15.

Abe, Koki, Toshiyuki Yano, Masaya Tanno, et al.. (2019). mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1865(12). 165552–165552. 46 indexed citations

16.

Oshima, H, Takayuki Miki, Atsushi Kuno, et al.. (2018). Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats. Journal of Pharmacology and Experimental Therapeutics. 368(3). 524–534. 103 indexed citations

17.

Kuno, Atsushi, Masaya Tanno, Takayuki Miki, et al.. (2017). Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes. Scientific Reports. 7(1). 5311–5311. 29 indexed citations

18.

Nakata, Kei, Takayuki Miki, Masaya Tanno, et al.. (2017). Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus. PLoS ONE. 12(12). e0188689–e0188689. 17 indexed citations

19.

Nakata, Kei, Takayuki Miki, Masaya Tanno, et al.. (2016). Abstract 17519: Distinct Impacts of Sleep-disordered Breathing on Glycemic Variability in Patients With and Without Heart Failure. Circulation. 1 indexed citations

20.

Nakata, Tomoaki, Kei Nakata, & Akiyoshi Hashimoto. (2016). Recent Developments and Future Directions of Sympathetic Nervous Function Imaging. 2(1). 146–151. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact